Social Media Ideas for Lly

Stock Split Watch: Is Eli Lilly (LLY) Stock Next?

Shares recently traded at $1,280 each, so a split wouldn't be surprising.

How to Buy Eli Lilly Stock (LLY)

Pharmaceuticals and the stock market may seem like two completely different worlds to beginner investors, but Eli Lilly and Company proves otherwise. Its stock has delivered exc...

This New Zepbound Study Could Be Great News for Eli Lilly Investors

The high-flying healthcare leader looks unstoppable right now.

Eli Lilly Q2: Strong Results Further Strengthen The Investment Thesis

Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years

Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.

LVL

LVL Anonymous (not verified) Thu, 09/03/2026 - 12:46 field_thread_url https://cafepharma.com/boards/threads/lvl.715758/ board name...

Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031

And it will likely be the first company in the sector to get there.

Lloyds Banking Group plc (LYG) Q2 2026 Earnings Call Transcript

AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock.

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

CSL Limited (CSLLY) Q4 2026 Earnings Call Transcript

Eli Lilly Just Announced a Major Acquisition. Here's What It Means.

The drug giant added to its immunotherapy portfolio.

StockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss

Lilly now expects to rack up between $85 billion and $87 billion in revenue this year, up 2.4% to 3.7% from its previous range of between $82 billion and $85 billion. That change r...

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Years

Maybe you should, too.

Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win

Novo Nordisk is finally getting one up on its biggest rival.

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences]]>

Alnylam (ALNY) Q2 2026 Earnings Call Transcript

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow

StockWatch: Lilly’s Up-to-$3.8B Deal for AtaiBeckley a Good Trip for Psychedelic Drugs, Analysts and Investors Agree

Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion—of which Lilly will pay $2.8 billion upfront. The deal, set to close in the third quarter, expands Lilly’s neuroscien...